Quantcast

Latest Clinical trial Stories

2014-07-16 16:24:01

ABERDEEN, Scotland and SINGAPORE, July 16, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd [http://www.taurx.com ] announced it has achieved its target enrollment of 833 subjects into one of its two ongoing multi-center Phase III clinical trials of LMTX(TM) [http://taurx.com/lmtx-for-ad ], a tau aggregation inhibitor, for the treatment of Alzheimer's Disease [AD]. This placebo-controlled clinical trial (Protocol TRx-237-015 [http://taurx.com/015-clinical-study.html ]) has...

2014-07-16 12:28:25

Cognitive function is primary endpoint COPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ -- Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as the primary endpoint for their phase 2 trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. SYN120 is in development for the treatment of Parkinson's disease and other cognitive...

2014-07-16 12:27:23

COSTA MESA, Calif., July 16, 2014 /PRNewswire-iReach/ -- WCCT Global, a contract research organization headquartered in Southern Californian announced today the successful completion of a large phase I clinical trial. The study protocol required that WCCT Global enroll 180 patients that would stay in their phase I Clinical Pharmacology Unit for an extended period of time. WCCT Global was able to randomize and accommodate all the needed patient cohorts without delays. WCCTG...

2014-07-16 08:29:22

SER-109 demonstrated remarkably high clinical cure rate and excellent safety profile CAMBRIDGE, Mass., July 16, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has completed enrollment for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic designed for the treatment of recurrent Clostridium difficile Infection...

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-15 23:14:33

Achieve is conducting a Phase III, randomized, placebo-controlled study to evaluate the safety and effectiveness of a new viscoelastic hydrogel, for the treatment of osteoarthritis of the knee. Birmingham, AL (PRWEB) July 15, 2014 *To see if you qualify for this OA Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you may receive...

2014-07-15 23:14:30

Avail is conducting a Phase 2, randomized, placebo-controlled clinical research study to evaluate the efficacy, safety and pharmacokinetics of an experimental spray treatment for qualified participants with mild to moderate osteoarthritis (OA) of the knee. DeLand, FL (PRWEB) July 15, 2014 *To see if you qualify for this Osteoarthritis Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost...

2014-07-15 23:07:05

Announcing the Latest Version of the Market-Leading Clinical Conductor CTMS Rochester, NY (PRWEB) July 15, 2014 The Clinical Conductor CTMS team is proud to announce yet another major advancement in CTMS technology. With the latest release of Clinical Conductor, the market-leading CTMS again provides unparalleled advances in both features and functionality designed to give users even greater levels of increased efficiency and maximized profits. Most prominently seen in this release are...

2014-07-15 16:27:20

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Type 2 Diabetes Global Clinical Trials Review, H1, 2014https://www.reportbuyer.com/product/2160179/Type-2-Diabetes-Global-Clinical-Trials-Review-H1-2014.htmlType 2 Diabetes Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Type 2 Diabetes Global Clinical Trials Review, H1, 2014" provides data on the Type 2 Diabetes clinical trial scenario. This report...

2014-07-15 12:29:33

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Autism Global Clinical Trials Review, H1, 2014https://www.reportbuyer.com/product/2160177/Autism-Global-Clinical-Trials-Review-H1-2014.htmlAutism Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Autism Global Clinical Trials Review, H1, 2014" provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related